colorectal cancer diagnosis kit has granted patent for inventions -凯发app

recolontm, an non-invasive colorectal cancer diagnosis, has been granted patent for inventions in china in august, 2017.


recolontm is the 1st crc molecular diagnostic product that uses mir-92a as biomarker from china. microrna has good stability and repeatability in stool1. mir-92a, a small non-coding rna, is located at human chromosome 13 mir-17-92 gene cluster. mir-92a promotes the crc cell proliferation and migration by targeting pten, klf4 and p21 genes1. compared with normal population, the mir-92a level was significantly increased in stool of individuals with crc lesions and crc patients2,3. hence, mir-92a could be used as a sensitive and specific molecular biomarker for crc diagnostics



retrecolontm mir-92a assay kit is jointly developed by shenzhen genebiohealth co., ltd and the chinese university of hong kong. the mir-92a assay technology was awarded the 2nd prize of the national natural science award of china in 2017. recolontm is a quantitative real-time pcr detection of mir-92a in human stool specimen. recolontm achieves 71.76% sensitivity and 90.07% specificity for crc diagnosis. by co-working with existing clinical tests, recolontm serves as an effective tool for crc screening, early diagnosis and postoperative monitoring.


references:

1. schreuders, e. h. et al. colorectal cancer screening: a global overview of existing programmes. gut 64, 1637-1649, doi:10.1136/gutjnl-2014-309086 (2015).

2. zhu, j. et al. epidemiological trends in colorectal cancer in china: an ecological study. digestive diseases and sciences 62, 235-243, doi:10.1007/s10620-016-4362-4 (2017).

3. chen, w. et al. cancer statistics in china, 2015. ca: a cancer journal for clinicians 66, 115-132, doi:10.3322/caac.21338 (2016).

recolontm, an non-invasive colorectal cancer diagnosis, has been granted patent for inventions in china in august, 2017.


recolontm is the 1st crc molecular diagnostic product that uses mir-92a as biomarker from china. microrna has good stability and repeatability in stool1. mir-92a, a small non-coding rna, is located at human chromosome 13 mir-17-92 gene cluster. mir-92a promotes the crc cell proliferation and migration by targeting pten, klf4 and p21 genes1. compared with normal population, the mir-92a level was significantly increased in stool of individuals with crc lesions and crc patients2,3. hence, mir-92a could be used as a sensitive and specific molecular biomarker for crc diagnostics


retrecolontm mir-92a assay kit is jointly developed by shenzhen genebiohealth co., ltd and the chinese university of hong kong. the mir-92a assay technology was awarded the 2nd prize of the national natural science award of china in 2017. recolontm is a quantitative real-time pcr detection of mir-92a in human stool specimen. recolontm achieves 71.76% sensitivity and 90.07% specificity for crc diagnosis. by co-working with existing clinical tests, recolontm serves as an effective tool for crc screening, early diagnosis and postoperative monitoring.


references:

1. schreuders, e. h. et al. colorectal cancer screening: a global overview of existing programmes. gut 64, 1637-1649, doi:10.1136/gutjnl-2014-309086 (2015).

2. zhu, j. et al. epidemiological trends in colorectal cancer in china: an ecological study. digestive diseases and sciences 62, 235-243, doi:10.1007/s10620-016-4362-4 (2017).

3. chen, w. et al. cancer statistics in china, 2015. ca: a cancer journal for clinicians 66, 115-132, doi:10.3322/caac.21338 (2016).


prev
next
article classification:
share to:
about us
product
news
lessons
service
telephone:
0755-86573093
shenzhen genebiohealth co., ltd
fax:( 86)755-86573069   e-mail:service   address:buliding a9-2f, tianliao industrial park a, taoyuan street, nanshan district, shenzhen, china
凯发app copyright ©2018 shenzhen genebiohealth co., ltd 凯发app copyright

buy online
follow wechat